Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Published:2020-12 Issue:12 Volume:21 Page:1563-1573
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Powles Thomas,Plimack Elizabeth R,Soulières Denis,Waddell Tom,Stus Viktor,Gafanov Rustem,Nosov Dmitry,Pouliot Frédéric,Melichar Bohuslav,Vynnychenko Ihor,Azevedo Sergio J,Borchiellini Delphine,McDermott Raymond S,Bedke Jens,Tamada Satoshi,Yin Lina,Chen Mei,Molife L Rhoda,Atkins Michael B,Rini Brian I

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

2. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

3. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Motzer;N Engl J Med,2019

4. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study;Heng;J Clin Oncol,2009

5. KEYTRUDA® (pembrolizumab) for injection, for intravenous use,2020

Cited by 535 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toripalimab in combination with chemotherapy effectively suppresses local recurrence and metastatic sarcomatoid renal cell carcinoma: A case report;World Journal of Clinical Cases;2024-10-06

2. Notfälle in der Medikamentösen Tumortherapie;TumorDiagnostik & Therapie;2024-09

3. The treatment of metastatic renal cell carcinoma;Deutsches Ärzteblatt international;2024-08-23

4. Contemporary Management of Renal Cell Carcinoma: A Review for General Practitioners in Oncology;Current Oncology;2024-08-22

5. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy;Journal of Translational Medicine;2024-08-09